<DOC>
	<DOCNO>NCT00274833</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . Giving radiation therapy together temozolomide erlotinib surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give radiation therapy together temozolomide erlotinib work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy , Temozolomide , Erlotinib Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival overall survival patient newly diagnose glioblastoma multiforme treat adjuvant radiotherapy , temozolomide , erlotinib hydrochloride . - Evaluate toxicity regimen patient . OUTLINE : This non-randomized study . Patients receive oral temozolomide daily day 1-42 undergo concurrent radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Four week completion radiotherapy temozolomide , patient receive oral temozolomide daily day 1-5 . Treatment temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients also receive oral erlotinib hydrochloride daily begin day 1 radiotherapy continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven glioblastoma multiforme Newly diagnose disease Has undergone diagnostic biopsy surgical resection within past 28 day PATIENT CHARACTERISTICS : ECOG 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 9 g/L Serum creatinine total serum bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Alkaline phosphatase &lt; 2.5 time ULN No severe underlie disease ( include HIV chronic hepatitis B C infection ) Fertile patient must use effective contraception Not pregnant nursing No medical condition could interfere oral administration temozolomide erlotinib hydrochloride No malignancy within past 3 year exception surgically cure carcinoma situ cervix , nonmelanoma skin cancer , adequately treated stage I II cancer patient complete remission No active infection No condition would preclude ability patient follow closely Cleveland Clinic PRIOR CONCURRENT THERAPY : No prior radiotherapy chemotherapy cancer No prior cranial radiotherapy No concurrent enzymeinducing antiepileptic drug No prior temozolomide erlotinib hydrochloride No concurrent antineoplastic therapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) chemotherapy No concurrent electron , particle , implant boost radiotherapy No concurrent radiosurgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>